Back to Search
CAN DANG, PHARMD
PHARMD
Pharmacist
NPI: 1275716565Individual
Specialties, Licenses & Credentials
Research & Publications (20)
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible.
PMID 18952555·Clin Breast Cancer·2008
3-trial
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
PMID 18323546·J Clin Oncol·2008
3-trial
Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
PMID 16503859·Expert Rev Anticancer Ther·2006
6-review
Tenascin-C patterns and splice variants in actinic keratosis and cutaneous squamous cell carcinoma.
PMID 16965426·Br J Dermatol·2006
8-other
Identification of dysregulated genes in cutaneous squamous cell carcinoma.
PMID 16865251·Oncol Rep·2006
8-other
Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.
PMID 16764744·Clin Breast Cancer·2006
6-review
E6/E7 expression of human papillomavirus types in cutaneous squamous cell dysplasia and carcinoma in immunosuppressed organ transplant recipients.
PMID 16792764·Br J Dermatol·2006
8-other
Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer.
PMID 12972365·Cancer Treat Rev·2003
8-other
Clinical significance of expression of p21 and p53 proteins and proliferating cell nuclear antigen in pancreatic cancer.
PMID 14612290·Hepatobiliary Pancreat Dis Int·2002
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5801 QUEENS BLVD
WOODSIDE, NY 11377 - Phone
- (718) 779-6431
Quick Facts
- NPI
- 1275716565
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile